Emibetuzumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | HGFR |
| Clinical data | |
| Other names | LY2875358 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6356H9810N1694O2014S48 |
| Molar mass | 143719.12 g·mol−1 |
Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC
This drug was developed by Eli Lilly & Company.